US 11364227
Sphingosine kinase 2 inhibitor for treating coronavirus infection
granted A61KA61K31/435A61K31/4409
Quick answer
US patent 11364227 (Sphingosine kinase 2 inhibitor for treating coronavirus infection) held by RedHill Biopharma Ltd. expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- RedHill Biopharma Ltd.
- Grant date
- Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K31/435, A61K31/4409, A61K31/495, A61K9/0053